Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vireo GrowthVREOF -0.61%47 3-Year EPS without NRI Growth Rate is 42.20% as of Jun. 2026, which is 120% above its 10-year median of 19.15. GuruFocus rates VREOF with a GF Score™ of 47/100 and a GF Value™ of $11.88 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 786 Drug Manufacturers companies, Vireo Growth ranks better than 84.61% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 42.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 27.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 7.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Vireo Growth was 84.20% per year. The lowest was -50.30% per year. And the median was 19.15% per year.
Vireo Growth (OTCPK:VREOF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Vireo Growth 3-Year EPS without NRI Growth Rate Related Terms
VREOF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Vireo Growth's 3-Year EPS without NRI Growth Rate falls into.
Vireo Growth 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 42.20% mean?
Vireo Growth (VREOF) has a 3-Year EPS without NRI Growth Rate of 42.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vireo Growth and its competitors. This is 120% above median its historical median of 19.15. According to the industry distribution chart, Vireo Growth ranks #121 out of 786 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Vireo Growth's 3-Year EPS without NRI Growth Rate too high?
Vireo Growth's current 3-Year EPS without NRI Growth Rate of 42.20% is 120% above median its 10-year median of 19.15. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.85. Vireo Growth's value of 42.20% is 328.4% above this industry median. Based on the distribution chart, Vireo Growth ranks #121 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vireo Growth has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #121 out of 786 companies for 3-Year EPS without NRI Growth Rate. This places Vireo Growth in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.85. Vireo Growth's value of 42.20% is 328.4% above this benchmark. While the company's 10-year median is 19.15 vs. the industry median of 9.85, Vireo Growth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.85, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current 3-Year EPS without NRI Growth Rate of 42.20% is 328.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vireo Growth and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current 3-Year EPS without NRI Growth Rate is 42.20%, which is 120% above median its own 10-year median of 19.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.88, compared to a current price of $10.54 — trading 11.3% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 42.20%, which is 120% above median its 10-year median of 19.15 and 328.4% above the Drug Manufacturers industry median of 9.85. Vireo Growth's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Vireo Growth (VREOF), the current 3-Year EPS without NRI Growth Rate is 42.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be undervalued.
The current stock price of $10.54 is trading 11.3% below its estimated GF Value™ of $11.88.
GuruFocus considers Vireo Growth to be Modestly Undervalued.
Key valuation signals for VREOF:
3-Year EPS without NRI Growth Rate: 42.20% (120% above median its 10-year median of 19.15)
GF Value™: $11.88 vs. price of $10.54 (11.3% below fair value)
Industry Position: 328.4% above the Drug Manufacturers median (#121 of 786)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
47GF Score
Get the complete analysis for VREOF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
